Clinical Trial Update: A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation [Phase 1]

View source ↗

Summary

Phase 1 research studying the safety and initial effectiveness of BAY 3771249 in people with advanced or metastatic colorectal cancer harboring a KRAS G12D muta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• BAY 3771249

Snippet

Sponsor: Bayer | Conditions: Advanced/Metastatic Colorectal Adenocarcinoma | Phase 1 | Status: NOT_YET_RECRUITING